TNXP Tonix Pharmaceuticals Holding Corp.
Price Chart
Executive Summary
Tonix Pharmaceuticals presented Phase 1 data for TNX-4800, a long-acting monoclonal antibody for seasonal prevention of Lyme disease, demonstrating favorable pharmacokinetics with serum concentrations detectable for up to 12 months and a half-life of 62–69 days. The company also highlighted preclinical work on TNX-801, a live attenuated horsepox-based vaccine candidate for smallpox and mpox, with plans for Phase 1 initiation in 2027 pending FDA clearance. No efficacy endpoints or clinical protection data were reported, and the announcement is primarily developmental in nature.
Actionable Insight
Traders should monitor upcoming FDA feedback and initiation of the TNX-4800 field study in 2027 as next catalysts; while PK data is encouraging, absence of efficacy data limits near-term upside. Insider buying may suggest confidence, but no material financial updates were provided.
Key Facts
- TNX-4800 Phase 1 study showed serum concentrations remained quantifiable for >200 days at the lowest dose (0.5 mg/kg) and up to 350 days at higher doses (≥1.5 mg/kg)
- Mean half-life of TNX-4800 ranged from 62 to 69 days across dose groups
- TNX-4800 was generally safe and well-tolerated with no significant immunogenicity (anti-drug antibodies in <10% of subjects)
- No clinical efficacy data from human challenge or field studies were presented — only pharmacokinetic and safety data
- TNX-801 (horsepox vaccine) remains in pre-IND stage with Phase 1 expected in 2027 pending FDA clearance
- GMP investigational product for TNX-4800 expected in early 2027; field study planned for first half of 2027, CHIM study in 2028
Financial Impact
No immediate financial impact — data supports continued development but no commercial or revenue implications near-term
Risk Factors
- No efficacy data yet — protection against Lyme disease remains unproven in humans
- Development timelines are multi-year (field study in 2027, CHIM in 2028), increasing execution and funding risk
- Highly competitive landscape for Lyme prevention, including vaccines in development
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3260859 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 9, 2026
today
|
Insider Cluster
| $11.44 awaiting T+5 | awaiting T+5 | — | $11.71 (+2.36%) |
|
Jun 8, 2026
1d ago
|
8-K
| $11.05 awaiting T+5 | awaiting T+5 | — | $11.71 (+5.97%) |
|
May 15, 2026
25d ago
|
8-K
| $15.74 $12.77 | ▼ −18.87% | ▼ −19.83% | $11.71 (−25.60%) |
|
May 14, 2026
26d ago
|
Press Release
| $14.09 $14.00 | ▼ −0.64% | ▲ +0.08% | $11.71 (−16.89%) |
|
May 11, 2026
29d ago
|
8-K
| $13.28 $14.26 | ▼ −7.38% | ▼ −7.30% | $11.71 (+11.82%) |
|
Apr 29, 2026
5w ago
|
8-K
| $12.40 $13.50 | ▲ +8.87% | ▲ +5.76% | $11.71 (−5.56%) |
|
Apr 23, 2026
6w ago
|
8-K
| $12.49 $12.40 | ▼ −0.72% | ▼ −2.20% | $11.71 (−6.24%) |
|
Apr 15, 2026
7w ago
|
Press Release
| $14.34 $13.11 | ▼ −8.58% | ▼ −10.22% | $11.71 (−18.34%) |
|
Mar 26, 2026
10w ago
|
Press Release
| $13.75 $13.90 | ▲ +1.09% | ▼ −0.54% | $11.71 (−14.84%) |
|
Mar 23, 2026
11w ago
|
Press Release
| $15.34 $13.75 | ▼ −10.37% | ▼ −9.94% | $11.71 (−23.66%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access